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We initially performed a mutation screen of the coding region
of the MC4R in 808 extremely obese children and adolescents
and 327 underweight or normal-weight controls allowing for
a case-control study. A total of 16 different missense, non-
sense, and frameshift mutations were found in the obese study
group; five of these have not been observed previously. In
vitro assays revealed that nine [the haplotype (Y35X; D37V)
was counted as one mutation] of the 16 mutations led to im-
paired cAMP responses, compared with wild-type receptor
constructs. In contrast, only one novel missense mutation was
detected in the controls, which did not alter receptor function.
The association test based on functionally relevant mutations
was positive (P  0.006, Fisher’s exact test, one-sided). We
proceeded by screening a total of 1040 parents of 520 of the
aforementioned obese young index patients to perform trans-
mission disequilibrium tests. The 11 parental carriers of func-
tionally relevant mutations transmitted the mutation in 81.8%
(P  0.033; exact one-sided McNemar test). These results sup-
port the hypothesis that these MC4R mutations represent ma-
jor gene effects for obesity. (J Clin Endocrinol Metab 88:
4258–4267, 2003)
WORLDWIDE, DIFFERENT GROUPS have foundframeshift, nonsense, and missense mutations in the
melanocortin-4 receptor gene (MC4R) (1–15). The frameshift
and nonsense mutations are presumed to result in haploin-
sufficiency of the MC4R; original studies suggested a major
gene effect resulting in autosomal dominantly inherited obe-
sity (2, 4, 5). In this context, the term, major gene effect,
implies that the respective MC4R mutations have a high
penetrance and explain a high percentage of the phenotypic
variance. MC4R mutations have been detected in up to 6% of
obese individuals (15).
Currently, five frameshift mutations and one nonsense
mutation have been reported (2–5, 9, 14, as based on studies
published before March 2003). Their combined frequency
amounts to 0.59% in 1853 (extremely) obese individuals in
whom the coding region of the MC4R was completely
screened for mutations. None of these mutations were de-
tected in 826 unrelated normal weight controls, who were
also completely screened.
The functional implications of the previously identified 32
missense mutations (2–6, 9–15) are seemingly less clear: Two
missense variants (V103I and I251L) occur in approximately
2–3% and 1% of both obese and nonobese subjects from
European and North American populations (3, 5, 9, 14), re-
spectively; functional studies revealed no differences be-
tween these two variants and the wild-type receptor (3, 6, 16).
A third missense variant (T112M) has been shown to occur
infrequently in both normal-weight controls and obese in-
dividuals (5, 6, 9, 14); compatible with these data, a functional
effect of this variant was not detected in an in vitro assay
system (6). Recently three novel missense variants were de-
tected in normal-weight individuals (I102T, F202L, N240S)
(14). Unfortunately, functional studies were not performed
for these variants. All of the other missense mutations have
been found mainly or exclusively in extremely obese index
patients encompassing children, adolescents, and adults. For
some of the missense mutations, functional studies (3, 6, 9,
12, 16) have shown that the variants were either only partially
active (N62S, S127L, I137T, T150I, R165W, I170V, A244E,
I301T, I317T) or showed no activity (P78L, G98R, C271Y,
P299H), compared with wild-type receptors. Surprisingly,
one mutation that was identified in an extremely obese index
patient leads to a constitutively active receptor molecule
(L250Q) (3). Recently it was shown (15) that the mutated
receptor molecule is partially retained intracellularly.
In family studies, relatives who are carriers of the same
functionally relevant MC4R mutation as the respective index
patient have mostly been shown to be obese (2–5, 8–10, 12,
Abbreviations: BMI, Body mass index; CI, confidence interval; SSCP,
single-strand conformation polymorphism; TDT, transmission disequi-
librium test; TEAA, triethylammonium acetate.
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13), thus substantiating a major gene effect. However, single
carriers within these families were not overweight (3, 6,
8–10). Whereas one relative with a nonsense mutation (Y35X)
(8) had been obese before a heart attack, Vaisse et al. (3)
identified three lean family members with a frameshift mu-
tation (47–48insG) ascertained via an extremely obese car-
rier; the respective mutation leads to a truncation in the N
terminus of the protein. In the three lean relatives, obesity
had never occurred; no explanation for their leanness was
found. Farooqi et al. (9) detected homozygous carriers of a
missense mutation (N62S) in a consanguineous family. The
five homozygous mutation carriers of that family were ex-
tremely obese, whereas the heterozygous relatives were
nonobese, leading the authors to conclude that this MC4R
mutation confers a recessively transmitted form of obesity.
Kobayashi et al. (12) reported a missense mutation (G98R)
leading to a loss of function. The extremely obese Japanese
girl was homozygous for the mutation; the parents and the
sister, all heterozygous for the mutation, were overweight.
This mutation is seemingly associated with a codominant
form of obesity.
On the basis of these aforementioned findings, it is cur-
rently unclear to what extent mutations in MC4R indeed
influence body weight. In the original two publications (2, 4),
based on a single family each, the investigators had con-
cluded that MC4R mutations are compatible with dominant
inheritance of obesity. Ho and MacKenzie (16), who per-
formed functional studies, presumed that MC4R mutations
lead to haploinsufficiency of the receptor. However, indi-
viduals with large deletions in the chromosomal region (18q)
that harbors the MC4R are not obese. Thus, obesity might
result as a consequence of a dominant-negative effect of
MC4R mutations (17). Nonsense-mediated decay inhibits the
accumulation of nonsense- or frameshift-mutated mRNA
and thus minimizes the synthesis of truncated proteins with
potential dominant-negative effects. However, it was re-
cently shown that MC4R mRNA is not susceptible to non-
sense-mediated decay (18). Hence, it remains uncertain
whether the effect of the functionally relevant mutations is
due to haploinsufficiency or whether the mutated alleles
exert a dominant-negative effect. Very recently Lubrano-
Berthelier et al. (15) showed that approximately 80% of the
mutations identified in children and adolescents cause par-
tial or complete intracellular retention of the receptor.
The identification of lean carriers with frameshift muta-
tions (3) suggests that other genetic and/or specific envi-
ronmental factors are potentially prerequisites for the man-
ifestation of obesity in MC4R mutation carriers. Jacobson et
al. (14) have since questioned the relationship between MC4R
mutations and severe obesity. A priori, obesity, which rep-
resents the right end of the body mass index (BMI) distri-
bution, is caused by both environmental and genetic factors.
Among the latter, both additive and nonadditive factors con-
tribute to this quantitative phenotype (19). Most likely, mo-
nogenic forms of obesity are infrequent; thus, in genetic
terms oligogenic or polygenic inheritance of obesity should
be much more common.
In the current study, we addressed the question of whether
functionally relevant mutations in the MC4R (excluding the
known polymorphisms) are indeed compatible with an au-
tosomal dominant major gene effect on the phenotype ex-
treme obesity. For this purpose, we performed a mutation
screen in 808 extremely obese children and adolescents, 231
underweight (15th BMI percentile) and 96 normal-weight
(40–60th percentile) adult controls to enable a case-control
study. Functional studies were performed to determine
whether newly identified variants (especially missense mu-
tations) lead to impaired receptor function or even loss of
function of the MC4R. Up to this point, we adhered to the
procedure recently proposed for analyses of common dis-
eases (20). To further substantiate our findings, we screened
a total of 1040 parents of 520 of the aforementioned 808
extremely obese index patients. If indeed functionally rele-
vant MC4R mutations represent major gene effects, we hy-
pothesized that 1) parents should not or only infrequently
harbor additional functionally relevant mutations other than
those transmitted to the offspring and 2) that parents with
relevant mutations are obese.
Study subjects
We screened a total of 808 (456 female) extremely obese
German children and adolescents not known to be related
(mean BMI 32.5  6.3, mean age 13.9  2.7 yr) 231 healthy
underweight students (mean BMI 18.3  1.1 kg/m2, BMI 
15th percentile; mean age 25.3  3.8 yr) and 96 healthy,
normal-weight students (mean BMI 21.9  1.1 kg/m2, BMI
between 40th and 60th percentile, mean age 24.7  2.6 yr).
A total of 65.5% of the extremely obese children and ado-
lescents had an age- and gender-specific BMI percentile of 99
or greater as previously determined in a representative Ger-
man population sample (21). Additionally, the 1040 parents
(mothers: mean BMI 30.4  6.7 kg/m2, mean age 41.5  5.5
yr; fathers: mean BMI 30.4 5.7 kg/m2, mean age 44.5 6.2
yr) of those 520 obese children and adolescents were
screened, for whom both biological parents had been ascer-
tained before the MC4R mutation screen of the index patient,
thus guaranteeing a nonbiased transmission disequilibrium
test (TDT). Because we had excluded trios not compatible
with Mendelian inheritance in previous single nucleotide
polymorphism and microsatellite analyses, nonpaternity
should be a rare event only. Written informed consent was
given by all participants and in the case of minors, their
parents. The study was conducted in accordance with the
guidelines proposed in the Declaration of Helsinki and was
approved by the Ethics Committee of the University of Mar-
burg. The current analyses are based on a total of 2175 in-
dividuals, who were either newly screened for MC4R mu-
tations (n  1606) or had contributed to previous studies
(5, 8).
Phenotypic measurements
Body weights and heights of all probands were measured.
To illustrate the BMI distribution of both carriers and non-
carriers of different kinds of mutations in relationship to the
BMI distribution observed in the general population, we
plotted BMIs of the ascertained 808 obese children and ad-
olescents and of 1040 parents of a subgroup of 520 of these
index patients into BMI percentile curves, which were cal-
culated using quantile regression for the age span 8–70 yr
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based on the large and representative German National Nu-
trition Survey (21).
Materials and Methods
Molecular genetic method
PCRs were performed with primers amplifying the MC4-R in two
overlapping parts with the primer pairs MC4R-1 F/MC4R-1R (F1; 615
bp) and MC4R-2 F/MC4R-2R (F2, 622 bp; sequences have been de-
scribed previously) (5). Subsequently, single-strand conformation poly-
morphism (SSCP) analyses for mutations in the MC4-R were performed
at 4 C as described previously (5).
Additionally, all samples that revealed SSCP patterns indistinguish-
able from those of either one of the two known polymorphisms (V103I,
I251L) were reanalyzed with denaturing HPLC by using the WAVE
system (Transgenomic, Cheshire, UK). Melt temperatures for optimal
separation of homo- and heteroduplexes were deduced from the melting
profile of each amplicon’s DNA sequence using the WAVEmaker soft-
ware (version 4.0, Transgenomic). The PCRs were performed according
to standard protocols using 12 ng DNA (primers and PCR conditions as
described) (5). Five microliters of unpurified denatured-renatured PCR
products were loaded onto a preheated specific column (DNASep col-
umn, Transgenomic) and eluted from the column by a linear acetonitrile
gradient in a 0.1-m triethylammonium acetate (TEAA) buffer, pH 7, and
at a constant flow rate of 0.9 ml/min. The gradient was created by mixing
eluents A (0.1 m TEAA) and B (0.1 m TEAA, 25% acetonitrile). For
analyses of the MC4R F1 fragment, PCR products were eluted from the
column (61 C) by increasing buffer B from 54–59% within 30 sec and
from 59–68% within 4.5 min. The oven temperature for analyzing the
MC4R F2-fragment was set to 59 C and 60 C, respectively. For elution
of the MC4R F2 products, buffer B was increased from 54–59% within
10 sec and from 59–68% within 4.5 min. PCR amplicons with more than
one peak or differences in peak appearance were sequenced. All PCR
amplicons with SSCP or WAVE patterns deviant from the wild-type
pattern or the patterns created by the two polymorphisms were se-
quenced as described previously (5). One presumed I251L polymor-
phism (by SSCP) turned out to be a missense mutation (G181D). Another
individual turned out to harbor a frameshift mutation leading to a
deletion of GA at codon 250 in addition to the I251L polymorphism.
PCR-restriction fragment length polymorphism analyses
To reconfirm all identified variants (mutations and polymorphisms),
PCRs with subsequent diagnostic restriction fragment length polymor-
phism analyses were performed. For alleles that did not alter restriction
sites, specific primers were designed to either introduce artificial re-
striction sites or perform allele-specific PCR reactions. The [Y35X, D37V]
haplotype alleles were each detected by allele-specific PCR as described
previously (8); V103I was detected as described by Gotoda et al. (1). All
mutations and polymorphisms were reconfirmed by an independent
mutation analysis in every carrier of a variant.
Isolation and characterization of genomic DNA encoding
the MC4R
The gDNA of the human wild-type and mutant MC4R was amplified
by PCR using the primer pairs EcoRI-Koz-MC4r (forward primer), 5-
GAA TTC CCC ACC ATG GTG AAC TCC ACC CAC-3 and BamHI-
Stop-MC4r (reverse primer), 5-GGA TCC TTA ATA TCT GCT AGA
CAA GTC-3. The PCR fragment was inserted into the eukaryotic ex-
pression vector pSG5 (Stratagene, La Jolla, CA). PCR products were
further characterized by restriction endonuclease digestion and subse-
quent dideoxy sequencing (Perkin-Elmer, Boston, MA; Sequencer 310,
PE Biosystems).
Transient expression of wild-type and mutant MC4Rs and
functional assays
COS-7 cells were grown in DMEM supplemented with 10% fetal
bovine serum, 100 U/ml penicillin, and 100 g/ml streptomycin at 37
C in a humidified 5% CO2 incubator. For transient transfections COS-7
cells were split into 12-well plates (2  105 cells/well) and transfected
with 1 g plasmid DNA per well using Fugene reagent (Roche,
Mannheim, Germany). For cAMP measurements, cells were prelabeled
with [2,8-3H]adenine (2 Ci/well) (Perkin-Elmer). Assays were per-
formed 3 d after transfection. For cAMP assay, cells were washed once
in serum-free DMEM, followed by a preincubation with the same me-
dium containing 1 mm 3-isobutyl-1-methylxanthine (Sigma, Deisen-
hofen, Germany) for 20 min at 37 C in a humidified 5% CO2 incubator.
Subsequently cells were stimulated with appropriate concentrations of
-MSH (Sigma) for 1 h. Reactions were terminated by aspiration of the
medium and addition of 1 ml 5% trichloric acid. The cAMP content of
the cell extracts was determined by anion-exchange chromatography as
described (22): EC50 and Emax values were obtained from -MSH con-
centration-response curves (from 1 nm to 10 m -MSH/ml), using the
computer program GraphPad Prism (GraphPad Inc., San Diego, CA).
Data are indicated as means  sem of three to six independent exper-
iments, each carried out in duplicates.
The wild-type receptor showed Emax values approximately 10-fold
over wild-type basal; EC50 values were approximately 50 nm -MSH
(Table 1). We used the following criteria to define functional groups: (1)
loss of function was defined via mean Emax values less than 2-fold over
wild-type basal and undeterminable EC50 values; (2) reduced function
was defined via EC50 values that were more than 2.5-fold increased,
compared with wild-type with Emax values similar or slightly reduced
(P78L) to the wild-type; (3) like wild-type was defined by Emax and EC50
values similar to wild-type MC4R. Because the distinction between loss
of function and reduced function is arbitrary, we refer to the general
term, impaired function, for both groups (1 and 2). Two MC4R constructs
(S127L and P230L) showed constitutively active receptors, which were
characterized by increased basal cAMP levels, compared with the wild-
type receptor (see Table 1).
We used previous data to complement our functional classification
(see Table 1). When we initiated our functional analyses, two of our
detected mutations (T112M and R165W) had been functionally charac-
terized by others (Refs. 3 and 6, respectively). Very recently the func-
tional analyses of some more of the mutations identified in our study
were published (15); these data, which are consistent with our own data,
were not implemented in Table 1.
The nonsense mutation leading to a stop codon at amino acid position
35 of the MC4R is compatible only with a complete loss of function (15).
In vitro tests for this mutation were regarded as unnecessary. Because the
missense mutation at codon 37 (D37V) is always found on a haplotype
with the nonsense mutation, we did not perform functional assays
pertaining to this mutation.
Statistics, confirmatory analyses
The hypothesis of the study was the association of functionally rel-
evant mutations of the MC4R with extreme obesity. Therefore, the dif-
ference in the numbers of carriers of mutations leading to functional
impairment between 808 obese and 327 nonobese individuals were
investigated using a one-sided Fisher’s exact test. Subsequently TDTs
were conducted in trios based on those 520 of the 808 obese index
patients whose parents had also been ascertained. Here we also com-
bined the mutations leading to functional impairment to allow for a
one-sided TDT [(23); exact McNemar test] based on a larger number of
informative trios. The grouping of the mutations was based on the
results of functional assays as recommended by Hirschhorn and Alt-
shuler (20).
Exploratory analyses
Further association tests for the obese and nonobese groups and TDTs
were performed for other groupings of the observed mutations. Differ-
ences in age, BMI, and sd scores for BMI between carriers of mutations
leading to an impaired function vs. all other probands were analyzed
with two-sample t tests.
Odds ratio and genotype relative risk
Further analyses were conducted to estimate the risk to develop
extreme obesity because of a mutation leading to impaired function. We
estimated the odds ratio and a 95% confidence interval (CI) from the 808
obese cases and 327 nonobese controls. The genotype relative risk and
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a 95% exact binomial CI were estimated from those trios in which only
one of the four parental alleles harbored a mutation. The frequency of
the functionally relevant mutations and a 95% exact CI were estimated
from the nontransmitted parental alleles in the 520 trios. This estimate
is valid under the assumption of random mating and Hardy-Weinberg
equilibrium.
Results
Extremely obese children and adolescents
A total of 18 different nonsilent MC4R gene variants were
detected in 43 of the 808 obese children and adolescents in
whom the coding region of the MC4R was screened for
mutations (Table 1). Based on the underlying mutation on the
DNA level, these 18 variants can be classified as frameshift
(n  2), nonsense (n  1), and missense (n  15) mutations,
respectively. The frameshift and nonsense mutations are ex-
pected to interrupt the reading frame in the domains encod-
ing the N terminus (Y35X) and the fifth and sixth transmem-
brane domains [codon 211 deletion of CTCT (L211fsX216)
and codon 250 deletion of GA (L250fsX284)], respectively.
Nine of the missense mutations (S30F, D37V, I121T, S127L,
R165W, G181D; G252S, A244E, I317T) code for nonconser-
vative amino acid changes; six missense variants (P78L,
T112M, P230L, V95I; polymorphisms V103I and I251L) were
conservative. Two silent variants were detected (405AG,
972CT).
The two most common variants, V103I and I251L, which
have previously been identified as polymorphisms without
detectable functional implications (3, 6, 15), were observed
in 13 (1.61%) and nine (1.11%) of the obese individuals,
respectively.
The third most common mutations, Y35X and D37V, were
each observed in the same five (0.62%) individuals; these two
variants form a haplotype as revealed by parental transmis-
sion patterns. The missense mutations S30F, S127L, and
R165W and the frameshift mutation L211fsX216 were de-
tected in two individuals each, the remaining 10 variants, one
frameshift and nine missense mutations, were observed only
once in the study group (Table 1). Three index patients were
compound heterozygous for two missense variants each (a:
S127L and R165W; b: S30F and G252S; c: G181D and I251L),
as revealed by parental transmission patterns. The haplotype
S127L and V103I was identified in an index patient and her
mother.
The results of the heterologous in vitro studies based on the
ability of -MSH to stimulate cAMP production in addition
to previous findings in the literature (3, 6) are illustrated in
Table 1. Nine [the haplotype (Y35X; D37V) was counted as
one mutation] of the 16 different nonsilent mutations showed
an impaired function. In the applied assay, the single non-
sense, two frameshift (L211fsX216, L250fsX284), and two
missense mutations (V95I, G181D) each led to a loss of func-
tion. Four missense mutations (P78L, I121T, R165W, A244E)
resulted in an altered receptor function, which we crudely
classified as reduced in function. MC4R harboring either one
of the remaining four missense mutations (S30F, T112M,
G252S, I317T) or the polymorphisms I251L and V103I were
functionally indistinguishable from the wild-type receptor.
The missense mutations S127L and P230L showed elevated
basal cAMP levels, indicating a constitutively active receptor.
Adult underweight and normal-weight controls
Among the 231 underweight and 96 normal-weight stu-
dents, a total of eight carriers of the 103I allele were identi-
fied. The second polymorphism (I251L) was detected in
seven individuals, one of whom also harbored allele 103I. No
frameshift or nonsense mutations were detected among these
327 students. A single conservative missense mutation was
found in a normal-weight individual (T178M). The cAMP
assay (Table 1) revealed that the T178M missense mutation
seemingly does not affect receptor function. Finally, a single
silent mutation (579CT) was detected in an underweight
proband.
Association analysis
Association analyses (Table 2) were complicated by the
fact that the detected MC4R variants were rare and had
different functional implications. The analyses were based on
our own and previously (3, 6) generated functional data.
Because of uncertainties as to their functional implications,
the two mutations leading to a constitutively active receptor
(S127L and P230L) were excluded from these analyses. When
all mutations leading to impaired (loss of or reduced func-
tion) function were combined, the association test was sig-
nificant (one sided P 0.006). Post hoc analyses revealed that
separate analyses of the frameshift plus nonsense mutations
and the missense mutations show trends for association
within each group (descriptive, two-sided: P 0.114 and P
0.124, respectively; Table 2).
TDTs
Our subsequent analyses were based on trios recruited via
those 520 of the 808 extremely obese index patients whose
TABLE 2. Association tests for carriers of at least one mutation (the polymorphisms V103I and I251L are not included) of the
melanocortin-4 receptor gene (percentage of respective study group in parentheses) in 808 obese children and adolescents and 327 healthy
underweight and normal weight controls
No. of individuals with
at least one functionally
relevant mutationa
Frameshift and nonsense
mutations Missense mutations
808 Obese children and adolescents 15 (1.86) 8 (0.99) 12 (1.49)
327 Controls 0 (0) 0 (0) 1 (0.31)
P valueb 0.006c 0.114d 0.124d
Carriers of mutations that form a haplotype ([Y35X; D37V]) and compound heterozygotes (compound 1: S127L and R165W; compound 2: S30F
and G252S) were each counted once.
a See Table 1.
b Fisher’s exact test: c one-sided; d two-sided.
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parents had also been ascertained. We also combined the
mutations leading to functional impairment to allow for a
TDT (23) based on a larger number of informative trios. A
total of 11 heterozygous carriers of mutations leading to a
functional impairment were detected among the 1040 par-
ents (the two mutations leading to constitutively active re-
ceptors were again excluded from the analyses). All parents
were completely screened by SSCP; non-Mendelian trans-
missions were not detected. The confirmatory test revealed
nine transmissions and two nontransmissions (P  0.033
exact McNemar test, one-sided; Table 3). The two nontrans-
mitted mutations (the nonconservative missense mutation
S94R and the frameshift mutation Y320fsX354) both lead to
an impaired function (Table 1). The results of all post hoc TDT
analyses are shown in Table 3.
Odds ratio and genotype relative risk
For the combined set of mutations leading to impaired
function, we estimated the odds ratio, genotype relative risk,
and allele frequency. Because no functionally relevant mu-
tation was observed in the 327 controls and 15 of the 808
obese individuals were carriers of mutations associated with
an impaired function, the odds ratio estimate results in ,
the exact 95% CI ranges from 1.47 to . Based on the
nontransmitted parental alleles (which were found to result
in an impaired function in the in vitro assays), the estimate
for the frequency of functionally relevant mutations in the
general population is 0.19% (95% CI: 0.02%–0.69%). Based on
the observed nine transmissions and two nontransmissions
of mutations associated with an impaired function in our 520
trios, we estimated the genotype relative risk of heterozy-
gous carriers of functionally relevant mutations as 4.5; the
95% CI ranges from 0.9 to 42.8.
Percentile plots: extremely obese children and adolescents
Figure 1, A and B, illustrates BMI of those 21 extremely
obese young index patients with frameshift, nonsense,
and/or missense mutations (excluding the two polymor-
phisms) in relationship to both the 787 extremely obese non-
mutation carriers (including carriers of one or the other poly-
morphism, in whom no other nonsilent mutation was
present) and population-based gender-specific BMI percen-
tiles. Three mutations (Y35X, R165W, S30F) occurred in both
genders. Except for two variants (S30F and S127L), all mu-
tations in the females led to a receptor with impaired function
(Fig. 1A). BMI of the eight male mutation carriers clustered
in the middle to upper range of the BMI distribution formed
by all male obese subjects (Fig. 1B); four of the respective
mutations were associated with an impaired receptor func-
tion. The variants detected in the other four male carriers led
to receptors compatible with unaltered MC4R function; one
coded for a constitutively active receptor molecule.
The extremely obese patients harboring mutations leading
to an impaired function were heavier than noncarriers (mean
sd scores  3.1  0.6 in carriers vs. 2.6  0.6 in noncarriers,
descriptive P  0.01, t test, two-sided). The 22 carriers of
either one of the two polymorphisms skewed over the whole
BMI and age range in both males and females (data not
shown).
Percentile plots: parental study group
All 1040 parents of 520 of the total of 808 obese children
and adolescents were also screened for MC4R mutations (Fig.
2, A and B). Fifteen different nonsilent (including the two
polymorphisms) and two different silent (405CA, 972CT)
variants were detected in these 1040 parents.
Five of the seven mutations found among the mothers lead
to an impaired function (Table 1, Fig. 2A) and all seven
mutation carriers had BMI in the 85th centile or greater.
Among the fathers, two of the nine mutation carriers had a
BMI below the 85th percentile, one of these below the 50th
percentile. Our in vitro assays revealed that the two variants
of the normal weight fathers are seemingly functioning like
the wild-type receptor. Finally, parents with mutations as-
sociated with an impaired function (n 11) all had BMI 85th
BMI percentile or greater.
Discussion
We aimed to further clarify the role of MC4R mutations in
obesity. We detected association of functionally relevant
MC4R mutations with extreme obesity by genotyping the
largest obese study group as of today and normal-weight
controls. Whereas it has been common practice to extend
pedigrees only upon detection of a mutation carrier, we
systematically screened all 1040 parents of 520 obese children
and adolescents irrespective of their MC4R genotype.
Thereby we were also able to identify parental variants not
transmitted to their offspring. The major advantage of this
procedure is that we were able to perform a TDT and use a
family-based approach to estimate the epidemiological rel-
evance of MC4R mutations leading to functional impairment.
Both our case-control study and the TDT are compatible with
the notion that MC4R mutations, which are associated
with an impaired function in in vitro assays, are compatible
TABLE 3. Transmission disequilibrium tests for melanocortin-4 receptor gene mutations in 520 obese children and adolescents and both
of their parents
All mutations leading to
impaired functiona
All identified frameshift and
nonsense mutations
All identified missense
mutations
Transmitted 9 5 8
Nontransmitted 2 1 2
Transmission rate 81.8 83.3 80.0
P valueb 0.033c 0.219d 0.109d
If within a trio both parents harbored a variant/haplotype, all transmissions and nontransmissions were counted. The polymorphisms V103I
and I251L were excluded.
a See Table 1.
b Exact McNemar test: c one-sided, d two-sided.
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with a major gene effect. Whereas the original reports had
already suggested that MC4R mutations lead to extreme
obesity (2, 4), observations of lean carriers without a known
cause for their leanness (3) cast doubt on the original as-
sumption. Very recently the role of MC4R mutations in hu-
man obesity has even been questioned (14).
To evaluate the functional relevance of the identified
MC4R mutations, COS-7 cells were transiently transfected
with different receptor cDNAs, and functional studies were
performed. To assess receptor function at a proximal step of
the cellular signaling cascade, we directly measured second-
messenger production and determined agonist-induced
intracellular cAMP accumulation. Based on these in vitro
studies and published data (3, 6), we formed two main non-
overlapping categories (for criteria see Materials and Methods)
to classify the mutations: (1) impaired function (loss of func-
tion and reduced function) and (2) like wild-type. This cat-
egorization excludes the two mutations that turned out to
lead to constitutively active receptors (P230L and S127L,
Table 1). Vaisse et al. (3) also described a constitutively active
receptor in an obese individual; the respective receptor pro-
teins are partially retained intracellularly (15). This result is
in line with previous data indicating that expression of con-
stitutively active receptors is often reduced (24). Addition-
ally, such receptors have been described to be structurally
unstable (25). Hence, we cannot exclude that both S127I and
P230L entail an impaired function. Nevertheless, based on
the uncertain functional classification of the two identified
constitutively active receptor variants, we excluded them
from the association and TDT analyses.
We chose the umbrella term, impaired function, for both
loss of function and reduced function because our subcat-
egorization is somewhat arbitrary. Our in vitro results are
compatible with the previous data (9, 15). Because only one
FIG. 1. A and B, BMI percentile curves,
age 5–30 yr. To illustrate the BMI dis-
tribution of both carriers and noncarri-
ers of different kinds of mutations in
relationship to the BMI distribution ob-
served in the general population, BMI
of the ascertained 808 obese children
and adolescents (A, 456 females; B, 352
males) were plotted into BMI percentile
curves (P10, 10th percentile; P50, 50th
percentile; P90, 90th percentile), as de-
termined from the German National
Nutrition Survey (21). Black symbols,
carriers of mutations leading to a re-
duced function or mutations leading to
loss of function in in vitro assays; small
circles, wild-type carriers; large unfilled
circles, carriers of mutations with func-
tional properties not distinguishable
from wild type; squares, carriers of non-
sense and frameshift mutations; large
circles, carriers of missense mutations.
Numbers indicate different mutations
(see Table 1).
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functional test was performed, we obviously cannot exclude
the possibility that single mutations associated with a normal
cAMP response could show impaired function in other as-
says. Indeed, recently Lubrano-Bertehlier et al. (15) showed
that one of the mutations (I317T), which we had classified as
like wild-type, showed impaired cell surface expression.
However, because these data are not available for all of our
identified mutations, we did not include this information in
the biometrical analyses. Furthermore, we did not test bind-
ing of MC4R antagonists. Finally, albeit unlikely, functional
alterations detected in in vitro assays do not necessarily imply
that the respective variants are also functionally deviant in
vivo.
The nine mutations leading to impaired function occurred
in 15 of the 808 obese individuals (1.9%; 95% CI 1.0–3.0%).
The frequency of mutation carriers among obese study
groups ranged from 0.5% to 6.3% in previous reports (2–6,
9–15). All currently known mutations and polymorphisms in
the coding region are seemingly randomly distributed; there
is no evidence for a mutational hotspot in DNA segments
coding for any of the domains of the receptor molecule.
The observation of the same haplotype formed by the
nonsense mutation Y35X and the missense mutation D37V in
five obese probands suggests a common founder for 0.62%
of our study population. Indeed, we have previously shown
that two index patients ascertained in two different German
states (Bavaria and Hessia) are second-degree cousins (8).
Because all other mutations occurred only once or twice, the
thrifty genotype hypothesis (26) is not readily substantiated.
Only a single female index patient with a BMI of 48.5 kg/m2,
one of the highest in the total study group, was compound
heterozygous for two functionally relevant mutations (Fig.
1A), indicating that compound heterozygotes are not de-
tected disproportionately in our sample.
Our confirmatory analyses, which substantiate association
between MC4R mutations and extreme childhood and ado-
lescent obesity, were based on pooling of functionally rele-
vant mutations, an approach recently recommended by
Hirschhorn and Altshuler (20). The significant ratio of 15
carriers of functionally relevant mutations in 808 obese in-
dividuals to 0 in 327 nonobese individuals is suggestive of a
major gene effect of the respective mutations on the pheno-
FIG. 2. A and B, BMI percentile curves, age 25–65
yr. To illustrate the BMI distribution of both car-
riers and noncarriers of different kinds of muta-
tions in relationship to the BMI distribution ob-
served in the general population, BMI of the 1040
parents (A, 520 mothers, and B, 520 fathers) of a
subgroup of 520 of the 808 index patients were
plotted into BMI percentile curves (P10, 10th per-
centile; P50, 50th percentile; P90, 90th percentile),
as determined from the German National Nutri-
tion Survey (21). Black symbols, carriers of muta-
tions leading to a reduced function mutations lead-
ing to loss of function in in vitro assays; small
circles, wild-type carriers; large unfilled circles,
carriers of mutations with functional properties
not distinguishable from wild type; squares, carri-
ers of nonsense and frameshift mutations; large
circles, carriers of missense mutations. Numbers
indicate different mutations (see Table 1).
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type extreme obesity (one-sided Fisher’s exact test: P 0.006,
lower confidence limit of the odds ratio: 1.47). Obviously,
large-scaled epidemiological studies are required to obtain
more exact estimates of the genetic effects and the population
frequencies of the different MC4R mutations. Based on our
data, we predict that they will be detectable almost only in
the uppermost BMI strata. Indeed, among our index patients,
carriers of mutations leading to impaired function had a
higher BMI than patients carrying either wild-type alleles or
alleles not associated with an impaired function.
Our approach to pool functionally relevant mutations for
TDT analyses was also based on the recommendation for
association studies (20). The mutations leading to an im-
paired function (loss of function and reduced function) had
a transmission rate of 81.8% (P  0.033, Table 3). All related
post hoc TDTs (Table 3) also showed that all mutations (non-
sense, frameshift, and missense) were preferentially trans-
mitted to the obese offspring. The two nontransmissions
need to be interpreted in the light of the frequent occurrence
of obesity in both parents of our obese index patients. In our
study group approximately 25% of the index patients have
two obese (BMI 30 kg/m2) parents. Assortative mating (27,
28) and common environmental effects as well as the sam-
pling procedure in itself (Dempfle, A., unpublished data)
need to be considered as underlying this observation. If both
parents are obese, obese offspring can genetically result from
a single or more than one gene transmitted from either one
or both of the parents.
Estimation of the genotype relative risk for heterozygous
carriers of mutations leading to functional impairment in-
dicates a 4.5-fold increased genotype relative risk (95% CI
0.9–42.8) to become obese (BMI  90th centile) for carriers
of mutations leading to functional impairment, compared
with noncarriers. However, the large 95% CI encompasses 1,
and the upper confidence limit indicates that the relative risk
might be substantially greater than 4.5. Because of the high
percentage of bilinear parental obesity, the genotype relative
risk may be underestimated in our study. As a result of the
low frequency of functionally relevant mutations in the
MC4R, these are evidently not relevant for the majority of
obese individuals.
In conclusion, we tested for association and transmission
disequilibrium of MC4R mutations in early-onset extreme
obesity. Both approaches critically depend on the joint anal-
yses of the functionally relevant mutations and their correct
functional classification (see Ref. 20). Based on the signifi-
cantly higher frequency of functionally relevant mutations in
obese, compared with nonobese, individuals and the subse-
quent significant TDT, we conclude that MC4R mutations are
compatible with a major gene effect for the development of
obesity. This hypothesis is further supported by the genotype
relative risk estimate of 4.5 (95% CI 0.9–42.8). In combination
with the small population frequency of mutation carriers, the
results indicate that MC4R mutations have a low epidemi-
ological but a high individual relevance.
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